Revvity (RVTY) Stock Price, News & Analysis

Company Overview

Revvity, Inc. is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding. Headquartered in Waltham, Massachusetts, the company maintains a global footprint with R&D, manufacturing and customer support facilities across North America, Europe, Asia-Pacific and Latin America. Its solutions are used by pharmaceutical and biotechnology companies, academic and government research institutions, clinical laboratories, and industrial customers around the world.

Revvity is led by President and Chief Executive Officer Prahlad Singh, who brings extensive experience in the life sciences and diagnostics industries. Under his leadership, the company is focused on advancing its integrated product portfolio, expanding its digital and services offerings, and driving innovation to meet the evolving needs of researchers, clinicians and quality-critical manufacturers globally.

Key Stats

• Today's Range: $113.74 to $115.51
• 50-Day Range: $97.72 to $115.21
• 52-Week Range: $81.22 to $118.30
• Volume: 1.03 million shs
• Average Volume: 1.54 million shs
• Market Capitalization: $12.81 billion
• P/E Ratio: 54.67
• Dividend Yield: 0.24%
• Price Target: $108.36
• Consensus Rating: Hold

Revvity Stock Analysis - MarketRank™

Revvity scored higher than 57% of companies evaluated by MarketBeat, and ranked 409th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Revvity has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, 12 hold ratings, and no sell ratings.

Downside Risk

Revvity has a consensus price target of $108.36, representing about 5.6% downside from its current price of $114.81.

Amount of Analyst Coverage

Revvity has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 9.53%

Earnings Growth

Earnings for Revvity are expected to grow by 9.53% in the coming year, from $5.35 to $5.86 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revvity is 54.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 42.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revvity is 54.67, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 210.47.

Price to Earnings Growth Ratio

Revvity has a PEG Ratio of 2.08. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Revvity has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.72% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 6.75.

Change versus previous month

Short interest in Revvity has recently decreased by 2.63%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Revvity has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Revvity does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Revvity is 13.33%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Revvity will have a dividend payout ratio of 4.78% next year. This indicates that Revvity will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.90

News Sentiment

Revvity has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Revvity this week, compared to 5 articles on an average week.

MarketBeat Follows

3 people have added Revvity to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Revvity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,306.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of Revvity is held by insiders.

Percentage Held by Institutions

86.65% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/7 Dividend: 7/17/2026
• Ex-Dividend for 8/7 Dividend: 7/17/2026
• Last Earnings: 8/04/2026
• Today: 8/07/2026
• Dividend Payable: 8/07/2026
• Next Earnings (Estimated): 10/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:RVTY
• CIK: 31791
• Web: www.perkinelmer.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 11,000
• Year Founded: 1937

Price Target and Rating

• Average Price Target for Revvity: $108.36
• High Price Target: $125.00
• Low Price Target: $90.00
• Potential Upside/Downside: -5.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.10
• Trailing P/E Ratio: 54.67
• Forward P/E Ratio: 21.46
• P/E Growth: 2.08
• Net Income: $241.20 million
• Net Margins: 8.16%
• Pretax Margin: 8.96%
• Return on Equity: 8.34%
• Return on Assets: 5.01%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 1.80
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $2.86 billion
• Price / Sales: 4.48
• Cash Flow: $8.86 per share
• Price / Cash Flow: 12.96
• Book Value: $64.80 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 111,560,000
• Free Float: 110,612,000
• Market Cap: $12.81 billion
• Optionable: Optionable
• Beta: 1.07